The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PR and Ki67 in primary tumors and metastatic sites as biomarkers for benefit from endocrine therapy (ET) in metastatic breast cancer (mBC).
Cristiano Ferrario
No relevant relationships to disclose
Alberto Farolfi
No relevant relationships to disclose
Roberta Maltoni
No relevant relationships to disclose
Elisa Carretta
No relevant relationships to disclose
Elisabetta Melegari
No relevant relationships to disclose
Elisabetta Pietri
No relevant relationships to disclose
Andrea Rocca
No relevant relationships to disclose
Oriana Nanni
No relevant relationships to disclose
Dino Amadori
No relevant relationships to disclose